Cited by 207Cancer Genomics and DiagnosticsGenomics and Rare DiseasesChromatin Remodeling and Cancer

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Open access

Harris, Marian H., DuBois, Steven G., Glade Bender, Julia L., Kim, AeRang, Crompton, Brian D., Parker, Erin, Dumont, Ian P., Hong, Andrew L., Guo, Dongjing, Church, Alanna, Stegmaier, Kimberly, Roberts, Charles W. M., Shusterman, Suzanne, London, Wendy B., MacConaill, Laura E., Lindeman, Neal I., Diller, Lisa, Rodriguez-Galindo, Carlos, Janeway, Katherine A.·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2015.5689

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Pediatric cancers represent a unique case with respect to cancer genomics and precision medicine, as the mutation frequency is low, and targeted therapies are less available. Consequently, it is unknown whether clinical sequencing can be of benefit. OBJECTIVE: To assess the feasibility of identifying actionable alterations and making individualized cancer therapy (iCat) recommendations in pediatric patients with extracranial solid tumors. DESIGN, SETTING, AND PARTICIPANTS: Clinical sequencing study at 4 academic medical centers enrolling patients between September 5, 2012, and November 19, 2013, with 1 year of clinical follow-up. Participants were 30 years or younger with high-risk, recurrent, or refractory extracranial solid tumors. The data analysis was performed October 28, 2014. INTERVENTIONS: Tumor profiling performed on archived clinically acquired specimens consisted of mutation detection by a Sequenom assay or targeted next-generation sequencing and copy number assessment by array comparative genomic hybridization. Results were reviewed by a multidisciplinary expert panel, and iCat recommendations were made if an actionable alteration was present, and an appropriate drug was available. MAIN OUTCOMES AND MEASURES: Feasibility was assessed using a 2-stage design based on the proportion of patients with recommendations. RESULTS: Of 100 participants (60 male; median [range] age, 13.4 [0.8-29.8] years), profiling was technically successful in 89 (89% [95% CI, 83%-95%]). Median (range) follow-up was 6.8 (2.0-23.6) months. Overall, 31 (31% [95% CI, 23%-41%]) patients received an iCat recommendation and 3 received matched therapy. The most common actionable alterations leading to an iCat recommendation were cancer-associated signaling pathway gene mutations (n = 10) and copy number alterations in MYC/MYCN (n = 6) and cell cycle genes (n = 11). Additional alterations with implications for clinical care but not resulting in iCat recommendations were identified, including mutations indicating the possible presence of a cancer predisposition syndrome and translocations suggesting a change in diagnosis. In total, 43 (43% [95% CI, 33%-53%]) participants had results with potential clinical significance. CONCLUSIONS AND RELEVANCE: A multi-institution clinical genomics study in pediatric oncology is feasible and a substantial proportion of relapsed or refractory pediatric solid tumors have actionable alterations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01853345.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2015.5689

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,434
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kieżun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,198
Self-citation
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M. W., Ambrogio, L., Auclair, D., Wang, J., Song, Y. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0639 · Cited by 753
The Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A. N., Alexe, G., Kurek, K. C., Calicchio, M. L., Kieżun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 592
Self-citation
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
Self-citation

Show all 17 references

Sorted by citations

Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Self-citation
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R. D., van den Bosch, B. J. C., Paulussen, A. D. C., Xanthoulea, S., Blok, M. J., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 472
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
Wong, M., Mayoh, C., Lau, L. M. S., Khuong-Quang, D.-A., Pinese, M., Kumar, A., Barahona, P., Wilkie, E. E., Sullivan, P. A., Bowen-James, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1072-4 · Cited by 394
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0094 · Cited by 283
Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome
Rusch, M., Nakitandwe, J., Shurtleff, S. A., Newman, S., Zhang, Z., Edmonson, M. N., Parker, M. D., Jiao, Y., Ma, X., Liu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06485-7 · Cited by 219
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Hargrave, D. R., Bouffet, É., Tabori, U. Y., Broniscer, A., Cohen, K. J., Hansford, J. R., Geoerger, B., Hingorani, P., Dunkel, I. J., Russo, M. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2177 · Cited by 220
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations
Oberg, J. A., Bender, J. G., Sulis, M. L., Pendrick, D., Sireci, A. N., Hsiao, S. J., Turk, A. T., Cruz, F. S. D., Hibshoosh, H. H., Remotti, H. E., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0389-6 · Cited by 188
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Berlanga, P., Pierron, G., Lacroix, L., Chicard, M., de Beaumais, T. A., Marchais, A., Harttrampf, A. C., Iddir, Y., Larive, A., Soriano, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1136 · Cited by 174
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
Fiala, E. M., Jayakumaran, G., Mauguen, A., Kennedy, J. A., Bouvier, N., Kemel, Y. M., Fleischut, M. H., Maio, A., Salo‐Mullen, E. E., Sheehan, M. R., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00172-1 · Cited by 172
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
Stewart, E., McEvoy, J., Wang, H., Chen, X., Honnell, V., Ocarz, M., Gordon, B., Dapper, J., Blankenship, K., Yang, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.012 · Cited by 153
A first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Self-citation
Precision medicine in pediatric oncology
Forrest, S. J., Geoerger, B., & Janeway, K. A. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000570 · Cited by 179
Self-citation
Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial
Harttrampf, A. C., Lacroix, L., Deloger, M., Deschamps, F., Puget, S., Auger, N., Vielh, P. R., Varlet, P., Balogh, Z., Abbou, S. D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0381 · Cited by 155
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Suehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Padovan-Merhar, O. M., Raman, P., Ostrovnaya, I., Kalletla, K., Rubnitz, K. R., Sanford, E. M., Ali, S. M., Miller, V. A., Mossé, Y. P., Granger, M. P., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006501 · Cited by 135
Clinical utility of custom-designed NGS panel testing in pediatric tumors
Surrey, L. F., MacFarland, S. P., Chang, F., Cao, K., Rathi, K. S., Akgumus, G. T., Gallo, D., Lin, F., Gleason, A., Raman, P., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0644-8 · Cited by 131
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations
Villani, A., Davidson, S., Kanwar, N., Lo, W. W., Li, Y., Cohen‐Gogo, S., Fuligni, F., Edward, L.-M., Light, N. D., Layeghifard, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00474-y · Cited by 126
Advances in sarcoma diagnostics and treatment
Dancsok, A. R., Asleh, K., & Nielsen, T. O. (2016) · Oncotarget · doi:10.18632/oncotarget.12548 · Cited by 118
Recent progress in the treatment of cancer in children
Butler, E. B., Ludwig, K. F., Pacenta, H. L., Klesse, L. J., Watt, T. C., & Laetsch, T. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21665 · Cited by 130
Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101
Nagasubramanian, R., Wei, J. L., Gordon, P., Rastatter, J. C., Cox, M. C., & Pappo, A. S. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26026 · Cited by 116
Identification of NTRK fusions in pediatric mesenchymal tumors
Pavlick, D. C., Schrock, A. B., Malicki, D. M., Stephens, P. J., Kuo, D. J., Ahn, H., Turpin, B. K., Allen, J. M., Rosenzweig, M. R., Badizadegan, K., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26433 · Cited by 105
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 101
Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra
Chmielecki, J., Bailey, M., He, J., Elvin, J. A., Vergilio, J., Ramkissoon, S. H., Suh, J. H., Frampton, G. M., Sun, J., Morley, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1106 · Cited by 98
Self-citation
Precision medicine in pediatric oncology: Lessons learned and next steps
Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 94
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Kieran, M. W., Goumnerova, L. C., Manley, P. E., Chi, S. N., Marcus, K. J., Manzanera, A. G., Polanco, M. L. S., Guzik, B. W., Aguilar-Córdova, E., Diaz-Montero, C. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noy202 · Cited by 91
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations
George, S. L., Izquierdo, E., Campbell, J., Koutroumanidou, E., Proszek, P., Jamal, S., Hughes, D., Yuan, L., Marshall, L. V., Carceller, F., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.027 · Cited by 86
OncoKids
Hiemenz, M., Ostrow, D. G., Busse, T., Buckley, J. D., Maglinte, D. T., Bootwalla, M., Done, J., Ji, J., Raca, G., Ryutov, A., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.06.009 · Cited by 80
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
Moreno, L., Pearson, A. D. J., Paolettí, X., Jiménez, I., Geoerger, B., Kearns, P. R., Zwaan, C. M., Doz, F., Baruchel, A., Vormoor, J. H., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.59 · Cited by 80
The Future of Precision Oncology
Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612613 · Cited by 92
Precision-guided treatment in high-risk pediatric cancers
Lau, L. M. S., Khuong-Quang, D.-A., Mayoh, C., Wong, M., Barahona, P., Ajuyah, P., Senapati, A., Nagabushan, S., Sherstyuk, A., Alteköester, A.-K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03044-0 · Cited by 77
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27595 · Cited by 72
Self-citation
Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1
Kumamoto, T., Yamazaki, F., Nakano, Y., Tamura, C., Tashiro, S., Hattori, H., Nakagawara, A., & Tsunematsu, Y. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02011-w · Cited by 71
The paradox of precision medicine
Kimmelman, J., & Tannock, I. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0016-0 · Cited by 67
Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience
Marron, J. M., DuBois, S. G., Bender, J. G., Kim, A., Crompton, B. D., Meyer, S. C., Janeway, K. A., & Mack, J. W. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26137 · Cited by 70
Self-citation
Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors
Pincez, T., Clément, N., Lapouble, E., Pierron, G., Kamal, M. T., Bièche, I., Bernard, V., Fréneaux, P., Michon, J. M., Orbach, D. H., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26365 · Cited by 66
Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes
Walsh, M. F., Ritter, D., Kesserwan, C. A., Sonkin, D., Chakravarty, D., Chao, E., Ghosh, R., Kemel, Y. M., Wu, G., Lee, K., et al. (2018) · Human Mutation · doi:10.1002/humu.23640 · Cited by 63
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
Church, A. J., Corson, L., Kao, P., Imamović, A., Reidy, D., Doan, D., Kang, W., Pinto, N. R., Maese, L. D., Laetsch, T. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01856-6 · Cited by 67
Self-citation
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’
Langenberg, K. P. S., Meister, M. T., Bakhuizen, J. J., Boer, J. M., van Eijkelenburg, N. K. A., Hulleman, E., Ilan, U., Looze, E. J., Dierselhuis, M. P., van der Lugt, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.09.001 · Cited by 70
Progress toward liquid biopsies in pediatric solid tumors
Weiser, D. A., West-Szymanski, D. C., Fraint, E., Weiner, S., Rivas, M. A., Zhao, C. W. T., He, C., & Applebaum, M. A. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09825-1 · Cited by 61
Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers
Khater, F., Vairy, S., Langlois, S., Dumoucel, S., Sontag, T., St-Onge, P., Bittencourt, H. N. D. S., Soglio, D. B. D., Champagne, J., Duval, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2906 · Cited by 61
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer
Mayoh, C., Mao, J., Xie, J., Tax, G., Chow, S., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3702 · Cited by 55
The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development
Langenberg, K. P. S., Looze, E. J., & Molenaar, J. J. (2021) · Cancers · doi:10.3390/cancers13174324 · Cited by 61
Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma
Rusert, J. M., Juarez, E. F., Brabetz, S., Jensen, J., Garancher, A., Chau, L. Q., Tacheva-Grigorova, S. K., Wahab, S., Udaka, Y. T., Finlay, D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1655 · Cited by 55
Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie
Basse, C., Morel, C., Alt, M., Sablin, M. P., Franck, C., Pierron, G., Callens, C., Melaabi, S., Masliah‐Planchon, J., Bataillon, G., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000339 · Cited by 52
Ushering in the next generation of precision trials for pediatric cancer
DuBois, S. G., Corson, L., Stegmaier, K., & Janeway, K. A. (2019) · Science · doi:10.1126/science.aaw4153 · Cited by 53
Self-citation
Emerging Opportunities for Target Discovery in Rare Cancers
Sharifnia, T., Hong, A. L., Painter, C., & Boehm, J. S. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.002 · Cited by 51
Self-citation
Precision medicine in pediatric oncology
Burdach, S. E. G., Westhoff, M., Steinhauser, M., & Debatin, K. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0084-3 · Cited by 53
Genomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 51
ACCELERATE – Five years accelerating cancer drug development for children and adolescents
Pearson, A. D. J., Weiner, S. L., Adamson, P. C., Karres, D., Reaman, G. H., Rousseau, R. F., Blanc, P., Norga, K., Skolnik, J. M., Kearns, P. R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.033 · Cited by 50
Self-citation
Novel Therapies for Relapsed and Refractory Neuroblastoma
Zage, P. E. (2018) · Children · doi:10.3390/children5110148 · Cited by 52
Pediatric oncology enters an era of precision medicine
Seibel, N. L., Janeway, K. A., Allen, C. E., Chi, S. N., Cho, Y., Bender, J. G., Kim, A., Laetsch, T. W., Irwin, M. S., Takebe, N., et al. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.01.002 · Cited by 47
Self-citation
Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience
Marks, L. J., Oberg, J. A., Pendrick, D., Sireci, A. N., Glasser, C. L., Coval, C., Zylber, R. J., Chung, W. K., Pang, J., Turk, A. T., et al. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00265 · Cited by 47
Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine
Dyer, M. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.010 · Cited by 48
Precision Medicine in Pediatric Oncology
Vo, K. T., Parsons, D. W., & Seibel, N. L. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.005 · Cited by 46
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
Lau, L. M. S., Mayoh, C., Xie, J., Barahona, P., MacKenzie, K. L., Wong, M., Kamili, A., Tsoli, M., Failes, T. W., Kumar, A., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114608 · Cited by 45
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion
Subbiah, V., Holmes, O., Gowen, K. A., Spritz, D., Amini, B., Wang, W., Schrock, A. B., Meric‐Bernstam, F., Zinner, R., Piha-Paul, S. A., et al. (2016) · Oncology · doi:10.1159/000449204 · Cited by 42
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
Kytölä, V., Topaloĝlu, Ü., Miller, L. D., Bitting, R. L., Goodman, M. M., D`Agostino, R. B., Desnoyers, R. J., Albright, C. A., Yacoub, G., Qasem, S. A., et al. (2017) · Theranostics · doi:10.7150/thno.20355 · Cited by 40
Copy-number analysis identified new prognostic marker in acute myeloid leukemia
Nibourel, O., Guihard, S., Roumier, C., Pottier, N., Terré, C., Paquet, A. C., Peyrouze, P., Geffroy, S., Quentin, S., Alberdi, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.265 · Cited by 41
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers
Samuel, G., Crow, J., Klein, J. B., Merchant, M. L., Nissen, E., Koestler, D. C., Laurence, K., Liang, X., Neville, K. A., Staggs, V. S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27678 · Cited by 41
Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Malone, C. F., Dharia, N. V., Kugener, G., Forman, A. B., Rothberg, M. V., Abdusamad, M., Gonzalez, A. E., Kuljanin, M., Robichaud, A. L., Conway, A. S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1213 · Cited by 37
Self-citation
Multiplexed detection of microRNA biomarkers from tumor cells and tissues with a homogeneous nano-photon switch
Huang, R. Q., Liao, Y., Zhou, X., Fu, Y., & Xing, D. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.03.055 · Cited by 40
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium
Pikman, Y., Tasian, S. K., Sulis, M. L., Stevenson, K. E., Blonquist, T. M., Winger, B. A., Cooper, T. M., Pauly, M. G., Maloney, K. W., Burke, M. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0564 · Cited by 38
Self-citation
Genomics and Precision Medicine for Clinicians and Scientists in Hypertension
Dominiczak, A. F., Delles, C., & Padmanabhan, S. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08252 · Cited by 38
Emerging and investigational therapies for neuroblastoma
Applebaum, M. A., Desai, A. V., Bender, J. G., & Cohn, S. L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1304212 · Cited by 39
Precision Oncology in Sarcomas: Divide and Conquer
Pestana, R. C., Groisberg, R., Roszik, J., & Subbiah, V. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00247 · Cited by 36
Review: Ewing Sarcoma Predisposition
Gargallo, P., Yáñez, Y., Juan, A. D., Segura, V., Balaguer, J., Torres, B., Oltra, S., Castel, V., & Cañete, A. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00765-3 · Cited by 42
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor
Schienda, J., Church, A. J., Corson, L. B., Decker, B. J., Clinton, C. M., Manning, D. K., Imamović, A., Reidy, D., Strand, G. R., Applebaum, M. A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00281 · Cited by 34
Self-citation
Sequencing-based diagnostics for pediatric genetic diseases: progress and potential
Tayoun, A. N. A., Krock, B. L., & Spinner, N. B. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1209411 · Cited by 33
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 36
Radiosensitivity Differences between EGFR Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses
Anakura, M., Nachankar, A., Kobayashi, D., Amornwichet, N., Hirota, Y., Shibata, A., Oike, T., & Nakano, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153635 · Cited by 33
Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers
Rankin, A., Johnson, A., Roos, A., Kannan, G. S., Knipstein, J. A., Britt, N., Rosenzweig, M. R., Haberberger, J., Pavlick, D. C., Severson, E. A., et al. (2020) · The Oncologist · doi:10.1002/onco.13519 · Cited by 34
Clinical Utility of Precision Medicine in Pediatric Oncology: A Systematic Review
Lee, J., Gillam, L. H., Visvanathan, K., Hansford, J. R., & McCarthy, M. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00405 · Cited by 32
Healthcare professionals’ attitudes toward cancer precision medicine: A systematic review
Vetsch, J., Wakefield, C. E., Techakesari, P., Warby, M., Ziegler, D. S., O'Brien, T. A., Drinkwater, C., Neeman, N., & Tucker, K. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.05.001 · Cited by 31
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
Stankunaite, R., George, S. L., Gallagher, L., Jamal, S., Shaikh, R., Yuan, L., Hughes, D., Proszek, P., Carter, P. M., Pietka, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.042 · Cited by 30
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
Tsoli, M., Wadham, C., Pinese, M., Failes, T. W., Joshi, S. M., Mould, E. V. A., Yin, J. X. M., Gayevskiy, V., Kumar, A., Kaplan, W. H., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1491498 · Cited by 28
ARID1B alterations identify aggressive tumors in neuroblastoma
Lee, S. H., Kim, J.-S., Zheng, S., Huse, J. T., Bae, J. S., Lee, J. W., Yoo, K. H., Koo, H. H., Kyung, S., Park, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17500 · Cited by 26
Precision Medicine in Pediatric Neurooncology: A Review
Mochizuki, A. Y., Frost, I. M., Mastrodimos, M. B., Plant, A., Wang, A., Moore, T. B., Prins, R. M., Weiss, P. S., & Jonas, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00388 · Cited by 26
Innovations in Cancer Treatment of Children
Helms, L., Guimera, A. E., Janeway, K. A., & Bailey, K. M. (2023) · PEDIATRICS · doi:10.1542/peds.2023-061539 · Cited by 30
Self-citation
Precision oncology: lessons learned and challenges for the future
Yang, H., Shah, R. H., Tegay, D. H., & Onel, K. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201326 · Cited by 25
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
Murumägi, A., Ungureanu, D., Khan, S. A., Arjama, M., Välimäki, K. E., Ianevski, A., Ianevski, P., Bergström, R., Dini, A., Kanerva, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02067-z · Cited by 24
Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
Østrup, O., Nysom, K., Scheie, D., Schmidt, A. Y., Mathiasen, R., Hjalgrim, L. L., Olsen, T. E., Skjøth‐Rasmussen, J., Henriksen, B. M., Nielsen, F. C., et al. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00114 · Cited by 22
Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors
Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K., Ibáñez, G., You, D., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.002 · Cited by 23
Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors
Marron, J. M., Cronin, A. M., DuBois, S. G., Bender, J. G., Kim, A., Crompton, B. D., Meyer, S. C., Janeway, K. A., & Mack, J. W. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00176 · Cited by 24
Self-citation
Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours
Izquierdo, E., Yuan, L., George, S. L., Hubank, M. J. F., Jones, C., Proszek, P., SHIPLEY, J. M., Gatz, S. A., Stinson, C. L., Moore, A. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23000 · Cited by 20
Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers
Deyell, R. J., Shen, Y., Titmuss, E., Dixon, K., Williamson, L. M., Pleasance, E., Nelson, J., Abbasi, S., Krzywinski, M. I., Armstrong, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48363-5 · Cited by 21
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy
Nuryadi, E., Sasaki, Y., Hagiwara, Y., Permata, T. B. M., Sato, H., Komatsu, S., Yoshimoto, Y., Murata, K., Ando, K., Kubo, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25982 · Cited by 20
Precision medicine in Ewing sarcoma: a translational point of view
Gargallo, P., Juan, A. D., Yáñez, Y., Dolz, S., Segura, V., Castel, V., & Cañete, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02298-7 · Cited by 21
Perspectives and Experiences of Parents and Adolescents Who Participate in a Pediatric Precision Oncology Program: "When You Feel Helpless, This Kind of Thing Is Very Helpful"
Waldman, L., Hancock, K., Gallinger, B., Johnstone, B., Brunga, L., Malkin, D. M., Barrera, M. E., & Villani, A. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00444 · Cited by 19
Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
McGee, R. B., Oak, N., Harrison, L. H., Xu, K., Nuccio, R., Blake, A. K., Mostafavi, R. M., Lewis, S., Taylor, L. M., Kubal, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2482 · Cited by 20
A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib
Kumamoto, T., Aoki, Y., Sonoda, T., Yamanishi, M., Arakawa, A., Sugiyama, M., Shirakawa, N., Ishimaru, S., Saito, Y., Maeshima, A. M., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2553-9 · Cited by 19
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer
Keller, R. B., Mazor, T., Sholl, L. M., Aguirre, A. J., Singh, H., Sethi, N. S., Bass, A. J., Nagaraja, A. K., Brais, L. K., Hill, E. R., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00342 · Cited by 18
Self-citation
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial
Gatz, S. A., Harttrampf, A. C., Brard, C., Bautista, F. J., André, N., Abbou, S. D., Rubino, J., Rondof, W., Deloger, M., Rübsam, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2959 · Cited by 18
Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations
Oberg, J. A., Ruiz, J., Ali-Shaw, T., Schlechtweg, K., Ricci, A. M., Kung, A. L., Chung, W. K., Appelbaum, P. S., Bender, J. G., & Levine, J. M. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00104 · Cited by 18
Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future Directions
Brodeur, G. M., Diller, L., Nichols, K. E., Plon, S. E., Porter, C. C., & Malkin, D. M. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0423 · Cited by 17
Self-citation
Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemotherapy
Lee, Y. J., Kim, D., Shim, J. E., Bae, S., Jung, Y., Kim, S., Lee, H., Kim, S. H., Jo, S. B., Lee, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32729 · Cited by 17
Ethical Challenges in Pediatric Oncology Care and Clinical Trials
Benedetti, D. J., & Marron, J. M. (2021) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-63749-1_11 · Cited by 18
Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program
Poonnen, P. J., Duffy, J. E., Hintze, B. J., Shukla, M. P., Brettin, T. S., Conrad, N. R., Yoo, H., Guertin, C. M., Looney, J. A., Vashistha, V., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00075 · Cited by 17
Omic approaches to pediatric bone sarcomas
Tirtei, E., Cereda, M., Luna, E. D., Quarello, P., Asaftei, S. D., & Fagioli, F. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28072 · Cited by 16
Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors
Cullinan, N. M., Schiller, I., Giuseppe, G. D., Mamun, M. R. I., Reichman, L., Cacciotti, C., Wheaton, L., Caswell, K., DiMonte, B., Gibson, P. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00018 · Cited by 16

Authors: Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., Stegmaier, K., Roberts, C. W. M., Shusterman, S., London, W. B., MacConaill, L. E., Lindeman, N. I., Diller, L., Rodriguez-Galindo, C., & Janeway, K. A.
Affiliations: Boston Children's Hospital (US)
University of California, San Francisco (US)
Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, NewYork–Presbyterian Morgan Stanley Children’s Hospital, New York
Children's National (US)
Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Harvard University (US)
Brigham and Women's Hospital (US)
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts
Corresponding author: Janeway, Katherine A.
ORCID: Harris, Marian H.
DuBois, Steven G.
Kim, AeRang
Crompton, Brian D.
Hong, Andrew L.
Church, Alanna
Stegmaier, Kimberly
Roberts, Charles W. M.
Shusterman, Suzanne
London, Wendy B.
MacConaill, Laura E.
Lindeman, Neal I.
Diller, Lisa
Janeway, Katherine A.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-05-01
Volume: 2
Issue: 5
Pages: 608
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2015.5689
OpenAlex: W2269136289
Cited by: 206
References: 17
Citations by year: 2026: 10 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 20 · 2021: 25 · 2020: 10 · 2019: 30 · 2018: 26 · 2017: 28 · 2016: 14
FWCI: 13.60
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA013696)
Hyundai Hope On Wheels
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: pediatric solid tumors, tumor molecular profiling, actionable alterations, precision oncology, copy number alterations, cell cycle genes, cancer predisposition syndromes, translocation, targeted therapy, extracranial solid tumors, array comparative genomic hybridization, targeted next-generation sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks